Polymorphisms in the macrophage migration inhibitory factor gene and bone loss in postmenopausal women

Bone

Volumn 47, Issue 2, 2010, Pages 424-429

  Swanberg, Maria ^a   McGuigan, Fiona ^a   Ivaska, Kaisa K ^a   Gerdhem, Paul ^b   Lerner, Ulf H ^c,d   Bucala, Richard ^e   Kuchel, George ^f   Kenny, Anne ^f   Åkesson, Kristina ^a  

^a LUND UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bone remodeling; Genetics; Inflammation; Osteoimmunology; Osteoporosis

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; ACID PHOSPHATASE; BIOLOGICAL MARKER; ISOENZYME; ISOMERASE; MIF PROTEIN, HUMAN; TARTRATE-RESISTANT ACID PHOSPHATASE;

AGED; ARTICLE; BONE DENSITY; BONE REMODELING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; PHENOTYPE; POPULATION RESEARCH; POSTMENOPAUSE; PROMOTER REGION; GENETICS; HETEROZYGOTE; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ACID PHOSPHATASE; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COHORT STUDIES; FEMALE; GENE FREQUENCY; HAPLOTYPES; HETEROZYGOTE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; ISOENZYMES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE;

EID: 77955985353     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.009     Document Type: Article

References (52)

1. Cummings S.R., Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002, 359:1761-1767.
2. Holmberg A.H., Johnell O., Nilsson P.M., Nilsson J., Berglund G., Akesson K. Risk factors for fragility fracture in middle age. A prospective population-based study of 33, 000 men and women. Osteoporos. Int. 2006, 17:1065-1077.
3. Ferrari S. Human genetics of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:723-735.
4. Hardy R., Cooper M.S. Bone loss in inflammatory disorders. J. Endocrinol. 2009, 201:309-320.
5. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 2007, 7:292-304.
6. Dewhirst F.E., Stashenko P.P., Mole J.E., Tsurumachi T. Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. J. Immunol. 1985, 135:2562-2568.
7. Takayanagi H., Ogasawara K., Hida S., et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
8. Calandra T., Bucala R. Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J. Inflamm. 1995, 47:39-51.
9. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
10. Onodera S., Nishihira J., Iwabuchi K., et al. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular signaling pathways. J. Biol. Chem. 2002, 277:7865-7874.
11. Onodera S., Sasaki S., Ohshima S., et al. Transgenic mice overexpressing macrophage migration inhibitory factor (MIF) exhibit high-turnover osteoporosis. J. Bone Miner. Res. 2006, 21:876-885.
12. Oshima S., Onodera S., Amizuka N., et al. Macrophage migration inhibitory factor-deficient mice are resistant to ovariectomy-induced bone loss. FEBS Lett. 2006, 580:1251-1256.
13. Onodera S., Nishihira J., Yamazaki M., Ishibashi T., Minami A. Increased expression of macrophage migration inhibitory factor during fracture healing in rats. Histochem. Cell Biol. 2004, 121:209-217.
14. Leech M., Metz C., Hall P., et al. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum. 1999, 42:1601-1608.
15. Meazza C., Travaglino P., Pignatti P., et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002, 46:232-237.
16. Onodera S., Tanji H., Suzuki K., et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 1999, 11:163-167.
17. Baugh J.A., Chitnis S., Donnelly S.C., et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 2002, 3:170-176.
18. Renner P., Roger T., Calandra T. Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases. Clin. Infect. Dis. 2005, 41(Suppl 7):S513-S519.
19. Radstake T.R., Sweep F.C., Welsing P., et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum. 2005, 52:3020-3029.
20. Donn R., Alourfi Z., De Benedetti F., et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002, 46:2402-2409.
21. Bucala R. MIF and the genetic basis of macrophage responsiveness. Curr. Immunol. Rev. 2006, 2.
22. Gregersen P.K., Bucala R. Macrophage migration inhibitory factor, MIF alleles, and the genetics of inflammatory disorders: incorporating disease outcome into the definition of phenotype. Arthritis Rheum. 2003, 48:1171-1176.
23. Barton A., Lamb R., Symmons D., et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 2003, 4:487-491.
24. Wu S.P., Leng L., Feng Z., et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006, 54:3661-3669.
25. Hizawa N., Yamaguchi E., Takahashi D., Nishihira J., Nishimura M. Functional polymorphisms in the promoter region of macrophage migration inhibitory factor and atopy. Am. J. Respir. Crit. Care Med. 2004, 169:1014-1018.
26. Meyer-Siegler K.L., Vera P.L., Iczkowski K.A., et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 2007, 8:646-652.
27. Donn R.P., Plant D., Jury F., et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J. Invest. Dermatol. 2004, 123:484-487.
28. Mizue Y., Ghani S., Leng L., et al. Role for macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14410-14415.
29. Sanchez E., Gomez L.M., Lopez-Nevot M.A., et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun. 2006, 7:433-436.
30. Lenora J., Ivaska K.K., Obrant K.J., Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos. Int. 2007, 18:1297-1305.
31. Okabe R., Nakatsuka K., Inaba M., et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin. Chem. 2001, 47:1410-1414.
32. Seibel M.J. Biochemical markers of bone turnover Part II: clinical applications in the management of osteoporosis. Clin. Biochem. Rev. 2006, 27:123-138.
33. Ivaska K.K., Lenora J., Gerdhem P., Akesson K., Vaananen H.K., Obrant K.J. Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J. Clin. Endocrinol. Metab. 2008, 93:2622-2632.
34. Zhao J.H., Curtis D., Sham P.C. Model-free analysis and permutation tests for allelic associations. Hum. Hered. 2000, 50:133-139.
35. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
36. Zhong X.B., Leng L., Beitin A., et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 2005, 33:e121.
37. De Benedetti F., Meazza C., Vivarelli M., et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003, 48:1398-1407.
38. Bruyere O., Collette J., Delmas P., et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 2003, 44:259-265.
39. Garnero P., Hausherr E., Chapuy M.C., et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J. Bone Miner. Res. 1996, 11:1531-1538.
40. Gerdhem P., Ivaska K.K., Alatalo S.L., et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J. Bone Miner. Res. 2004, 19:386-393.
41. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin. Chem. 2001, 47:597-600.
42. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin. Chem. 2001, 47:74-80.
43. Ivaska K.K., Gerdhem P., Vaananen H.K., et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of nine years. J. Bone Miner. Res. 2009, 12:12.
44. Garai J., Lorand T. Macrophage migration inhibitory factor (MIF) tautomerase inhibitors as potential novel anti-inflammatory agents: current developments. Curr. Med. Chem. 2009, 16:1091-1114.
45. Jacquin C., Koczon-Jaremko B., Aguila H.L., et al. Macrophage migration inhibitory factor inhibits osteoclastogenesis. Bone 2009, 45:640-649.
46. Conaway H.H., Persson E., Halen M., et al. Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. FASEB J. 2009, 23:3526-3538.
47. Jansen I.D., Mardones P., Lecanda F., Oude Elferink R.P., et al. Ae2a, b-deficient mice exhibit osteopetrosis of long bones but not of calvaria. FASEB J. 2009, 23:3470-3481.
48. Wu Y., Torchia J., Yao W., et al. Bone microenvironment specific roles of ITAM adapter signaling during bone remodeling induced by acute estrogen-deficiency. PLoS ONE 2007, 2:e586.
49. Ashcroft G.S., Greenwell-Wild T., Horan M.A., Wahl S.M., Ferguson M.W. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am. J. Pathol. 1999, 155:1137-1146.
50. Ashcroft G.S., Mills S.J., Lei K., et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J. Clin. Invest. 2003, 111:1309-1318.
51. Nguyen T.V., Center J.R., Eisman J.A. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J. Bone Miner. Res. 2005, 20:1195-1201.
52. Sornay-Rendu E., Munoz F., Duboeuf F., Delmas P.D. Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. J. Bone Miner. Res. 2005, 20:1929-1935.